Genmab A/S (NASDAQ: GMAB) reported safety results for its experimental cancer drug rinatabart sesutecan combined with bevacizumab in patients with advanced ovarian cancer. The data comes from a Phase 1/2 study presented at the Society of Gynecologic Oncology Annual Meeting.

The combination showed a manageable safety profile with no new safety signals beyond those known for each drug individually, according to the company's press release. In the study, 40 patients with recurrent ovarian cancer received the combination treatment every three weeks.

The most common side effects included nausea (80% of patients), fatigue (67.5%), anemia (55%), and neutropenia (45%). Six patients experienced serious adverse events, and 11 patients required dose reductions. Two patients discontinued treatment, and no deaths were reported as treatment-related.

"Rina-S has shown a manageable safety profile as a monotherapy, and these safety data suggest that it may be combined with a standard-of-care therapy such as bevacizumab without significantly increasing the risk of additional side effects," said Dr. Cara Mathews, study investigator at Women and Infants Hospital, Brown University.

Rinatabart sesutecan is an antibody-drug conjugate that targets folate receptor alpha, which is found on certain cancer cells. The drug is being tested in multiple Phase 3 trials for various gynecologic cancers, including a study evaluating the combination with bevacizumab in patients with recurrent platinum-sensitive ovarian cancer.

Genmab is also studying the drug as a monotherapy in platinum-resistant ovarian cancer and endometrial cancer patients.